全文获取类型
收费全文 | 50526篇 |
免费 | 3638篇 |
国内免费 | 1444篇 |
专业分类
耳鼻咽喉 | 355篇 |
儿科学 | 590篇 |
妇产科学 | 562篇 |
基础医学 | 2832篇 |
口腔科学 | 788篇 |
临床医学 | 4155篇 |
内科学 | 7091篇 |
皮肤病学 | 588篇 |
神经病学 | 4156篇 |
特种医学 | 943篇 |
外国民族医学 | 2篇 |
外科学 | 3004篇 |
综合类 | 5856篇 |
现状与发展 | 1篇 |
一般理论 | 8篇 |
预防医学 | 5820篇 |
眼科学 | 744篇 |
药学 | 11745篇 |
37篇 | |
中国医学 | 4408篇 |
肿瘤学 | 1923篇 |
出版年
2024年 | 121篇 |
2023年 | 1003篇 |
2022年 | 1779篇 |
2021年 | 2630篇 |
2020年 | 2701篇 |
2019年 | 3197篇 |
2018年 | 3011篇 |
2017年 | 2663篇 |
2016年 | 2147篇 |
2015年 | 1750篇 |
2014年 | 3319篇 |
2013年 | 4945篇 |
2012年 | 3651篇 |
2011年 | 2839篇 |
2010年 | 2276篇 |
2009年 | 1834篇 |
2008年 | 1714篇 |
2007年 | 1787篇 |
2006年 | 1456篇 |
2005年 | 1319篇 |
2004年 | 1091篇 |
2003年 | 1090篇 |
2002年 | 786篇 |
2001年 | 719篇 |
2000年 | 605篇 |
1999年 | 517篇 |
1998年 | 379篇 |
1997年 | 382篇 |
1996年 | 398篇 |
1995年 | 315篇 |
1994年 | 255篇 |
1993年 | 277篇 |
1992年 | 263篇 |
1991年 | 200篇 |
1990年 | 179篇 |
1989年 | 149篇 |
1988年 | 165篇 |
1987年 | 111篇 |
1986年 | 122篇 |
1985年 | 227篇 |
1984年 | 191篇 |
1983年 | 144篇 |
1982年 | 157篇 |
1981年 | 112篇 |
1980年 | 108篇 |
1979年 | 92篇 |
1978年 | 89篇 |
1977年 | 71篇 |
1976年 | 62篇 |
1975年 | 62篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
51.
B. A. Reikhardt L. M. Belyavtseva O. G. Kulikova 《Bulletin of experimental biology and medicine》1992,113(5):682-684
Academician S. V. Anichkov Department of Pharmacology, Research Institute of Experimental Medicine, Academy of Medical Sciences, St. Petersburg. (Presented by Academician of the Academy of Medical Sciences A. N. Klimov.) Translated from Byulleten' Éksperimental'noi Biologii i Meditsiny, Vol. 113, No. 5, pp. 506–508, May, 1992. 相似文献
52.
[目的 ]观察解毒保肾汤治疗早期糖尿病性肾病的疗效 .[方法 ]将诊断为早期糖尿病性肾病的病人随机分为 2组 ,其中治疗组 4 4例给予解毒保肾汤 ,对照组 2 0例给予阳性对照药络汀新 ,观察治疗前后 2组病人的临床症状、空腹血糖、糖化血红蛋白量及尿蛋白排泄率等的变化 .[结果 ]治疗组总有效率为 80 % ,对照组总有效率为 6 5 % ,治疗组疗效优于对照组 ;治疗组在改善临床症状 ,降低空腹血糖、糖化血红蛋白量及尿蛋白排泄率等方面均优于对照组 .[结论 ]解毒保肾汤能够降低早期糖尿病性肾病患者的血糖、减少尿蛋白的排泄 ,具有一定的保护肾脏功能 ,对早期糖尿病性肾病有治疗作用 . 相似文献
53.
54.
A.M. Heugas A. Nummela M.A. Amorim V. Billat 《Journal of Science and Medicine in Sport》2007,10(5):280-287
It is difficult to interpret the training induced changes in middle-distance running, since numerous aerobic and anaerobic determinants of the performance are interdependent. Several aerobic and anaerobic tests are available but their results, particularly those from anaerobic tests, may be discordant, not providing univocal interpretation of training. The purpose of this study is to use a multidimensional approach to distinguish aerobic and anaerobic capacities assessed by two running tests on a track: the maximal anaerobic running test (MART) and V(O2max) tests. Eleven runners carried out two maximal tests on a synthetic track before and after a 4-week training period: (i) a maximal test to determine V(O2max), the velocity associated with V(O2max) (vV(O2max)) and the velocity at the lactate threshold (v(LT)), (ii) a maximal anaerobic running test to estimate anaerobic capacity. An all-out test run at v(LT)+50% of the difference between v(LT) and vV(O2max), known to be affected by both aerobic and anaerobic energy production, was used to test this approach. A principal components analysis (PCA) shows that two components (i.e., aerobic and anaerobic) explained 79% of the variation in the physiological variables. The PCA suggests that V(O2max) and MART tests assess the aerobic and the anaerobic capacities, respectively. In contrast, the performance in the all-out test is affected by both aerobic and anaerobic energy production. The PCA shows that v(LT) and DeltaP (difference between the maximal power of the MART and V(O2max)) are clear markers of the long-term endurance and the anaerobic capacity, respectively. This multidimensional approach can be a useful way to disentangle the aerobic and anaerobic components of track tests. 相似文献
55.
RGD-based strategies for selective delivery of therapeutics and imaging agents to the tumour vasculature 总被引:12,自引:0,他引:12
Kai Temming Raymond M. Schiffelers Grietje Molema Robbert J. Kok 《Drug Resistance Updates》2005,8(6):381-402
During the past decade, RGD-peptides have become a popular tool for the targeting of drugs and imaging agents to alphavbeta3-integrin expressing tumour vasculature. RGD-peptides have been introduced by recombinant means into therapeutic proteins and viruses. Chemical means have been applied to couple RGD-peptides and RGD-mimetics to liposomes, polymers, peptides, small molecule drugs and radiotracers. Some of these products show impressive results in preclinical animal models and a RGD targeted radiotracer has already successfully been tested in humans for the visualization of alphavbeta3-integrin, which demonstrates the feasibility of this approach. This review will summarize the structural requirements for RGD-peptides and RGD-mimetics as ligands for alphavbeta3. We will show how they have been introduced in the various types of constructs by chemical and recombinant techniques. The importance of multivalent RGD-constructs for high affinity binding and internalization will be highlighted. Furthermore the in vitro and in vivo efficacy of RGD-targeted therapeutics and diagnostics reported in recent years will be reviewed. 相似文献
56.
A recent series of randomized prospective clinical trials that compared rate control with rhythm control in patients with atrial fibrillation (AF) found no significant difference in primary outcome between the two strategies. However, these trials lacked clear criteria for defining "successful" rate or rhythm control. Various measures have been used to gauge the success of antiarrhythmic drug therapy, including time to first recurrence of AF, any AF recurrence, AF burden, and a reduction in symptoms. Determining the success of antiarrhythmic therapy can be relatively straightforward by using how patients feel during therapy as a key endpoint. Most patients are satisfied with a major reduction in symptomatic AF episodes and can live comfortably with occasional episodes of AF. For those who are bothered by even infrequent, brief AF episodes, a treatment regimen that eliminates nearly all AF recurrences is required, although often hard to achieve. Catheter ablation may be necessary to achieve a successful outcome in these patients. Suppression of AF in a patient at high risk of stroke does not, however, remove the need for concomitant warfarin therapy. The endpoints of ventricular rate control are not clear, and the recently published rhythm versus rate control trials lacked standard criteria for judging acceptable rate control. One relatively simple method is to try and achieve a 24-hour heart rate that mimics expected normal sinus rhythm. It is important to achieve good rate control to minimize symptoms and the risk of tachycardia-mediated cardiomyopathy. 相似文献
57.
Although non-steroidal anti-inflammatory drug-induced colopathy is well described, colonic perforations complicating non-steroidal anti-inflammatory drug intake are rare. We report a patient with rheumatoid arthritis who was on long-term diclofenac and presented with early colonic stricture formation and a caecal perforation, which to the best of our knowledge, has only been reported once before. It is important to suspect this diagnosis in patients on non-steroidal anti-inflammatory drug therapy who present with an acute abdomen. 相似文献
58.
溃疡散预防消化性溃疡复发临床观察 总被引:4,自引:0,他引:4
冀慧鹏 《河南中医学院学报》2004,19(4):34-35
目的 :观察溃疡散对消化性溃疡的抗复发治疗的临床效果。方法 :随机将 80例患者分成溃疡散治疗组 (4 2例 )和雷尼替丁对照组 (38例 )并同时观察两组患者治疗前后溃疡复发情况。结果 :治疗后治疗组溃疡复发率明显低于对照组 ,P <0 .0 1,两组对比有非常显著性差异。结论 :治疗组能明显的改善患者临床症状和降低消化性溃疡复发率。 相似文献
59.
江门市区实施乙型肝炎免疫策略16年的效果评价 总被引:6,自引:5,他引:1
目的:对江门市区1986年1月1日起全面实施的乙型肝炎(乙肝)免疫策略进行效果评价。方法:运用血清流行病学调查和疫情资料对比分析,比较实施“免疫策略”前后江门市区0~15岁人群乙肝发病率和感染率变化情况和乙肝表面抗体(抗-HBs)增长情况。结果:实施“免疫策略”后16年,0~15人群的乙肝发病率由1985年的367.39/10万,降至2001年的21.10/10万,下降94.26%;HBsAg阳性率由1985年的9.17%降至2002年的0.6%,下降93.46%;乙肝病毒总感染率由1985年的35.82%降至2002年的1.20%,下降96.65%;抗-HBs阳性率由1985年的24.64%上升到2002年的93.00%,上升2.77倍。结论:江门市区现行乙肝免疫策略效果显,能有效预防和控制地区性大面积的乙肝流行与传播。经过一代人的努力,能彻底改变人口乙肝高发病率和HBV高感染率及高携带率的状况。 相似文献
60.
不同营养支持方式对肠外瘘患者人体组成改善作用之比较 总被引:1,自引:1,他引:0
目的观察不同营养支持方式对肠外瘘患者人体组成的改善作用。方法30例肠外瘘患者分成两组各15例,分别给予全肠外营养支持(TPN)或全肠内营养支持(TEN),观察10d前后患者人体组成及血清胰岛素样生长因子-1(IGF-1)的变化。结果10d后所有患者的体重指数(BMI)与体细胞群(BCM)显著改善,而TEN组患者10d前后BCM增加幅度更明显,分别为(27.5±0.8)kg和(29.0±0.6)kg,Day10与Day0相比,P<0.01。两组患者总体水(TBW)与细胞内水(ICW)均增加,尤其ICW,Day10与Day0相比,TEN组P<0.01;TPN组P<0.05。血清IGF-1在两组患者治疗后均有显著上升,TEN组增加幅度更明显,Day0为(175.0±32.9)ng/ml,Day10为(255.5±34.1)ng/ml,与Day0比较,P<0.01;与TPN组比较,P<0.05。IGF-1的变化与BCM的改善显著正相关(r2=0.16,P<0.05)。结论营养支持治疗能显著改善肠外瘘患者的体细胞群,纠正细胞内、外水的异常分布,而EN作用更明显。 相似文献